About DuoCort Pharma
DuoCort Pharma is a company based in Helsingborg (Sweden) founded in 2004 by Jorgen Jonsson and Stanko Skrtic was acquired by ViroPharma in October 2011. DuoCort Pharma operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and AudentesTherapeutics, among others.
- Headquarter Helsingborg, Sweden
- Founders Jorgen Jonsson, Stanko Skrtic
- SectorsHealthcare
- Website duocort.com
- Social LinkedIn
- Acquired by ViroPharma (Oct 2011)
- Investors
- Acquired byViroPharma
(Oct 2011)
Investors in DuoCort Pharma
DuoCort Pharma has secured backing from 1 investor. Prominent investors backing the company include ViroPharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapies for viral and other infectious diseases | 1994 | viropharma.com | Exton, United States |
Investor details for DuoCort Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DuoCort Pharma
2 people are tracked at DuoCort Pharma (2 in leadership).
| Name | Role | Group |
|---|---|---|
Jorgen Jonsson | Co-Founder | Leadership |
Stanko Skrtic | Co-Founder | Leadership |
Complete people profiles for DuoCort Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DuoCort Pharma
2 dated milestones of DuoCort Pharma across 7 years, from founding to its latest funding, stage changes and deals.
- Founded DuoCort Pharma is founded.
- Exit Acquired by ViroPharma.
Competitors of DuoCort Pharma
DuoCort Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and AudentesTherapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| audentestx.com | 2013 | San Francisco, United States | $137.5M | 404 | Developer of therapeutics to treat rare genetic diseases | |
| amicusrx.com | 2002 | Philadelphia, United States | $91M | 517 | Developer of therapies for rare and orphan diseases | |
| fulcrumtx.com | 2015 | Cambridge, United States | $114.67M | 104 | Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases |
Detailed competitors of DuoCort Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to DuoCort Pharma
10 companies that operate in the same segment as DuoCort Pharma (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DuoCort Pharma
DuoCort Pharma was founded in 2004.
DuoCort Pharma is headquartered in Helsingborg, Sweden. It is registered at Helsingborg, Skane County, Sweden.
DuoCort Pharma was founded in 2004 in Helsingborg, Sweden, within the pharmaceutical sector targeting rare diseases. Focus is placed on enhancing glucocorticoid therapy for adrenal insufficiency through Plenadren, a once-daily dual-release hydrocortisone tablet featuring immediate and delayed release layers. Operations centered on this product until acquisition by ViroPharma in October 2011.
DuoCort Pharma's top competitors include Moderna, Spark Therapeutics and BridgeBio.
DuoCort Pharma has 1 investor. Key investors include ViroPharma.
Yes. DuoCort Pharma was acquired by ViroPharma in October 2011.